ストックスクリーナーアプリを入手
5.14
3.21%
0.16
Foghorn Therapeutics Inc (FHTX) 最新ニュース
FY2028 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
HC Wainwright Has Positive Forecast for FHTX FY2024 Earnings - Defense World
Charles Schwab Investment Management Inc. Grows Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wedbush Reduces Earnings Estimates for Foghorn Therapeutics - MarketBeat
HC Wainwright Issues Optimistic Estimate for FHTX Earnings - MarketBeat
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright - Yahoo Finance
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7% - MarketBeat
Foghorn Therapeutics shares target cut, buy rating on positive outlook By Investing.com - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) Given New $14.00 Price Target at Jefferies Financial Group - Defense World
Foghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Foghorn Therapeutics Advances Precision Oncology Pipeline - Yahoo Finance
Foghorn Therapeutics' SWOT analysis: chromatin pioneer's stock faces pivotal moment - Investing.com Canada
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat - MSN
Jefferies Financial Group Has Lowered Expectations for Foghorn Therapeutics (NASDAQ:FHTX) Stock Price - MarketBeat
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower - Benzinga
Foghorn Therapeutics Inc. Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - Marketscreener.com
Foghorn shifts focus from AML drug FHD-286 - Investing.com
Foghorn Therapeutics Ends Solo Development of FHD-286 - MarketWatch
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - The Manila Times
Foghorn Therapeutics Halts Key AML Drug Development After Phase 1 Results Fall Short - StockTitan
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX) - MSN
This Foghorn Therapeutics Insider Reduced Their Stake By 13% - Simply Wall St
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why - MSN
How the (FHTX) price action is used to our Advantage - Stock Traders Daily
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High? - MSN
(FHTX) Technical Pivots with Risk Controls - Stock Traders Daily
Foghorn Therapeutics patents new CBP degradation inducers - BioWorld Online
Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations - Nasdaq
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - The Manila Times
(FHTX) Trading Report - Stock Traders Daily
What is HC Wainwright’s Estimate for FHTX FY2024 Earnings? - Defense World
Wedbush Lifts Earnings Estimates for Foghorn Therapeutics - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report - Yahoo Finance
Research Analysts Issue Forecasts for FHTX FY2024 Earnings - MarketBeat
HC Wainwright Has Bullish Estimate for FHTX FY2024 Earnings - MarketBeat
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully - Yahoo Finance
Foghorn Therapeutics Inc (FHTX) Q3 2024 Earnings: Revenue Surpas - GuruFocus.com
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Foghorn Therapeutics Reports Third Quarter Highlights - TipRanks
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewswire
(FHTX) Investment Report - Stock Traders Daily
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Raymond James & Associates - Defense World
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk - Simply Wall St
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):